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Abstract
Background:  Regular use of nonsteroidal anti-inflammatory drugs (NSAIDs) is associated with a
decreased mortality from colorectal cancer (CRC). NSAIDs induce apoptotic cell death in colon cancer
cells in vitro and inhibit growth of neoplastic colonic mucosa in vivo however, the biochemical mechanisms
required for these growth inhibitory effects are not well defined. We previously reported that metabolites
of the NSAID sulindac downregulate extracellular-signal regulated kinase 1/2 (ERK1/2) signaling and that
this effect is both necessary and sufficient for the apoptotic effects of these drugs. The goal of this project
was to specifically test the hypothesis that sulindac metabolites block activation and/or expression of the
epidermal growth factor (EGF) receptor (EGFR).
Methods: HT29 human colon cancer cells were treated with EGF, alone, or in the presence of sulindac
sulfide or sulindac sulfone. Cells lysates were assayed by immunoblotting for phosphorylated EGFR
(pEGFR, pY1068), total EGFR, phosphorylated ERK1/2 (pERK1/2), total ERK1/2, activated caspase-3, and
α-tubulin.
Results: EGF treatment rapidly induced phosphorylation of both EGFR and ERK1/2 in HT29 colon cancer
cells. Pretreatment with sulindac metabolites for 24 h blocked EGF-induced phosphorylation of both EGFR
and ERK1/2 and decreased total EGFR protein expression. Under basal conditions, downregulation of
pEGFR and total EGFR was detected as early as 12 h following sulindac sulfide treatment and persisted
through at least 48 h. Sulindac sulfone induced downregulation of pEGFR and total EGFR was detected as
early as 1 h and 24 h, respectively, following drug treatment, and persisted through at least 72 h. EGFR
downregulation by sulindac metabolites was observed in three different CRC cell lines, occurred prior to
the observed downregulation of pERK1/2 and induction of apoptosis by these drugs, and was not
dependent of caspase activation.
Conclusion: These results suggest that downregulation of EGFR signaling by sulindac metabolites may
occur, at least in part, by inhibiting activation and expression of EGFR. Inhibition of EGFR signaling may
account for part of the growth inhibitory and chemopreventive effects of these compounds.
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Background
CRC is the second most common cause of cancer death in
the USA, with an estimated annual incidence of 104,950
and mortality of 56,290 in 2005 [1]. The lifetime risk of
developing CRC in the general US population is almost
6% [1]. Effective preventive measures could substantially
reduce both the incidence and mortality from CRC.
NSAIDs are one of the most widely studied and promising
groups of compounds for CRC prevention.
NSAIDs mediate their anti-inflammatory effects by inhib-
iting the enzymatic activity of cyclooxygenase-1 (COX-1)
and/or COX-2. Sulindac is a non-selective NSAID that
inhibits both COX-1 and COX-2. Sulindac is rapidly
metabolized in the liver to two major metabolites; 1)
sulindac sulfide, which is an active NSAID, and 2) sulin-
dac sulfone, which does not inhibit COX enzymatic activ-
ities and thus is not an NSAID. A large body of evidence
from cell culture, animal model, human epidemiologic
and clinical studies indicates that NSAIDs, including
sulindac and aspirin, have potent chemopreventive and
chemoregressive properties against colon cancer [2,3].
Although substantial evidence indicates that NSAIDs
inhibit the growth of neoplastic colonic mucosa, the bio-
logical and biochemical mechanisms responsible for the
growth inhibitory effects of these drugs are not well
defined. The chemopreventive and chemoregressive
effects of NSAIDs may not be due to inhibition of COX
alone as we have shown that sulindac sulfide and sulindac
sulfone both inhibit the phosphorylation of ERK1/2 in
HCT15 cells that do not express COX-1 or COX-2 [4].
Additionally, sulindac sulfone, the non-NSAID metabo-
lite of sulindac, has been shown, by our lab and others, to
induce apoptosis of cancer cells in vitro, prevent tumor for-
mation in animal models, and cause regression of adeno-
mas in familial adenomatous polyposis (FAP) [2,5].
Several biological mechanisms for the chemopreventive
effects of NSAIDs have been proposed including inhibi-
tion of proliferation, induction of apoptosis, and inhibi-
tion of angiogenesis. Our laboratory [5,6] and others [2]
have reported that NSAIDs inhibit growth of CRC cells in
culture primarily by the induction of apoptotic cell death.
An apoptotic mechanism was also suggested in human
adenomas treated with sulindac sulfone [7]. We have
reported that the apoptotic effect of sulindac is not
dependent on COX inhibition [4,5,8], but does appear to
be dependent on the downregulation of ERK1/2 [8].
Work from several laboratories has demonstrated sub-
stantial interactions between the biochemical effects of
NSAIDs and EGFR signaling. It is well established that
COX-2 protein expression is stimulated by EGF and
decreased by EGFR inhibitors [9]. Sulindac sulfide and
indomethacin inhibit TGFα induced prostaglandin pro-
duction and thymidine incorporation in RIE-1 cells [10],
and indomethacin, ibuprofen, and aspirin all block EGF-
induced Ca++ influx in Caco-2 colon cancer cells [11]. Fur-
thermore, combination therapy of NSAIDs and EGFR
antagonists display an additive effect against colon tumor
development in vivo [12] and two previous studies suggest
that NSAIDs might inhibit EGFR signaling [13,14].
Finally, sulindac has been shown to inhibit expression of
ErbB2/HER2 protein expression in rectal mucosa of FAP
patients [15]. The biochemical mechanisms by which
NSAIDs might modulate EGFR signaling has not been
addressed in any of these studies.
We have previously shown that sulindac sulfide and sulin-
dac sulfone inhibit ERK1/2 phosphorylation both basally
and in response to EGF [6], and that this inhibition is suf-
ficient [5] and necessary [8] for the apoptotic effect of
these drugs. The goal of this study was to specifically test
the hypothesis that sulindac metabolites block activation
and/or expression of EGFR (Figure 1). We report, for the
first time, that sulindac metabolites block both basal and
EGF induced phosphorylation of EGFR and downregulate
total EGFR protein expression. Together these results
identify a new target for the actions of sulindac and sug-
gest that inhibition of EGFR activation may be a major
biochemical mechanism for both the downregulation of
ERK1/2 signaling and the chemopreventive activity of
NSAIDs.
Methods
Reagents
Cell culture media and fetal bovine serum (FBS) were pur-
chased from Mediatech (Herndon, VA), antibiotic/
antimycotic solution (penicillin/streptomycin/fungi-
zone) from Life Technologies, Inc. (Grand Island, NY),
and tissue culture plates from Falcon (Franklin Lakes, NJ).
Primary antibodies raised against phosphorylated ERK1/2
(Thr202/Tyr204), total ERK1/2, and total EGFR were pur-
chased from Santa Cruz Biotechnology (Santa Cruz, CA);
primary antibody against phosphorylated
EGFR(Tyr1068), horseradish peroxidase-conjugated anti-
mouse and anti-rabbit secondary antibodies, and EGF
were purchased from Biosource (Camarillo, CA). Primary
antibody against caspase-3 (recognizes both full length
caspase-3 and cleavage products) and cleaved caspase-3
(recognizes only cleavage products of activated caspase-3
resulting from cleavage adjacent to Asp175) were
obtained from Cell Signaling Technology (Beverly, MA).
Immobilon-P membranes were purchased from Millipore
(Bedford, MA), chemiluminescent visualization reagents
from NEN (Boston, MA), and X-ray film from Pierce
(Rockford, IL). Sulindac sulfide was from LKT Laborato-
ries Inc. (St. Paul, MN). ZVAD-fmk (caspase inhibitor I)
and primary antibody against α-tubulin were purchasedJournal of Carcinogenesis 2005, 4:16 http://www.carcinogenesis.com/content/4/1/16
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from Calbiochem (San Diego, CA). Sulindac sulfone was
a generous gift from Cell Pathways Inc. (Horsham, PA).
Cell culture
HT29, Caco-2, and HCT116 human colon cancer cells
were purchased from American Type Culture Collection
(Manassas, VA). HT29 and HCT116 cells were maintained
in RPMI 1640 media supplemented with 10% FBS and
1% penicillin/streptomycin/fungizone solution; Caco-2
cells were maintained in DMEM media with 4 mM L-
glutamine adjusted to contain 1.5 g/L glucose and supple-
mented with 0.01 mg/ml human transferring, 10% FBS,
and 1% penicillin/streptomycin/fungizone solution.
Cells were plated and grown on tissue culture plates as
specified in the results section.
Morphologic quantitation of apoptotic cell death
An ethidium bromide/acridine orange double-dye mor-
phological assay [16] was used to quantitate apoptotic cell
death induced by sulindac metabolites. Cells were grown
in multi-well plates and given the appropriate drug treat-
ment. Three days after treatment, cells were harvested and
stained with a mixture of 100 µg/ml ethidium bromide
and 100 µg/ml acridine orange and then examined by flu-
orescence microscopy. Three fields of 100 cells each were
counted and the number of apoptotic cells (as determined
by nuclear morphology) as well as the number of living
and necrotic cells were expressed as a percentage of total
cells counted.
Cell lysates and Western immunoblotting
At time of harvest, cells were scraped from the plates,
washed with ice-cold phosphate buffered saline (PBS),
and pelleted at 2,400 × g for 5 min. Care was taken to keep
cells as cold as possible during the entire procedure. After
aspirating the supernatant, the cells were washed twice
with ice cold PBS and centrifuged. The cell pellet was lysed
in cell extraction buffer (10 mM Tris, pH 7.4, 100 mM
NaCl, 1 mM EDTA, 1 mM EGTA, 1 mM NaF, 20 mM
Na4P2O7, 2 mM Na3VO4, 1% Triton X-100, 10% glycerol,
0.1% SDS, 0.5% deoxycholate, 1 mM PMSF, 60 µg/mL
aprotinin, 10 µg/mL leupeptin, 1 µg/mL pepstatin) for 30
min, on ice, with vortexing at 10 min intervals. Lysates
were then centrifuged at 18,000 × g for 10 min at 4°C, and
supernatants collected. Protein concentrations of lysates
were determined by the method of Lowry [17].
Lysate samples (50 µg total protein) were separated by
sodium dodecyl sulfate-polyacrylamide gel electrophore-
sis and electrotransferred overnight onto Immobilon-P
polyvinylidene difluoride membranes. Nonspecific bind-
ing was blocked by immersing membranes in Tris-neutral
saline with 1% (w/v) dry milk and 0.05% Tween 20 for 30
min at room temperature, then blots were incubated with
pEGFR, pERK1/2, caspase 3, cleaved caspase-3, or α-tubu-
lin primary antibody while rocking at 37°C for 1 h.
Immunoreactive protein was detected by incubating blots
with horseradish peroxidase-conjugated secondary anti-
body for 1 h followed by chemiluminescent substrate for
1 min. Membranes probed for phospho-proteins were
then stripped and reprobed with total EGFR or total
ERK1/2 primary antibody followed by horseradish perox-
idase-conjugated secondary antibody as described above.
Non-stripped control blots were run to show that this
stripping procedure gave the same results as primary blots
with each antibody. Immunoreactive proteins were visu-
alized by exposure to radiographic film. Quantitation of
protein levels was determined by densitometry using a
visual imaging system (UN-SCAN-IT gel, Silk Scientific,
Inc., Orem, UT).
Statistical Analysis
Data was analyzed by one way ANOVA using a Newman-
Keuls multiple comparison test and statistical significance
accepted at p < 0.05 (GraphPad Prism 4.0, GraphPad Soft-
ware Inc., San Diego, CA).
The EGFR/MAPK/ERK1/2 signaling pathway Figure 1
The EGFR/MAPK/ERK1/2 signaling pathway. We have previously shown that sulindac metabolites inhibit both MEK1/2 
and ERK1/2 activation. The goal of this study was to determine if this inhibition is due to downregulation of the EGFR.Journal of Carcinogenesis 2005, 4:16 http://www.carcinogenesis.com/content/4/1/16
Page 4 of 12
(page number not for citation purposes)
Results
EGF induces phosphorylation of EGFR and ERK1/2 in 
HT29 human colon cancer cells
In order to verify that EGFR signaling was intact in our
cells, the effects of EGF treatment on the expression and
activation of EGFR and ERK1/2 in HT29 human colon
cancer cells was examined. It was observed that EGF rap-
idly induced a > 7 fold increase of pEGFR that was maxi-
mal at 10 min (Figure 2A and 2B). Similarly, EGF induced
a rapid, > 30 fold, increase of pERK1/2 that was also max-
imal at 10 min (Figure 2A and 2C). EGF-induced phos-
phorylation of EGFR and ERK1/2 persisted through 60
min, and was no longer detected at 24 h (data not shown).
Similar results were obtained in HCT116 and Caco-2
human colon cancer cell lines (data not shown).
Sulindac metabolites block EGF-induced phosphorylation 
of EGFR and ERK1/2, downregulate total EGFR protein, 
and induce apoptotic cell death
We next determined the effect of sulindac sulfide on EGF-
induced phosphorylation and expression of EGFR and
ERK1/2. Pretreatment of HT29 cells for 24 h with 40–160
µM sulindac sulfide blocked the ability of EGF to induce
phosphorylation of EGFR in a dose dependent fashion.
Total EGFR expression and EGF-induced phosphorylation
of ERK1/2 proteins was also downregulated following
EGF induces EGFR and ERK1/2 phosphorylation Figure 2
EGF induces EGFR and ERK1/2 phosphorylation. HT29 human colon cancer cells were grown to 80% confluence in 
medium containing 10% FBS then serum deprived for 48 h before treatment with vehicle (water), 10, or 100 ng/ml EGF. Cells 
were harvested 10 min after EGF treatment and lysates prepared for (A) Immunoblotting with antibodies raised against pEGFR 
(pY1068), total EGFR, pERK1/2, and total ERK1/2; α-tubulin immunoblots of the same lysates served as loading controls. The 
graphs show the densitometry results of the pEGFR bands (B) and pERK1/2 bands (C) normalized for the loading controls. 
Data represent mean of triplicate samples ± SD; statistical significance is denoted by ***p < 0.001 versus vehicle. Results shown 
in the figure are representative of 2 separate experiments each with triplicate samples.Journal of Carcinogenesis 2005, 4:16 http://www.carcinogenesis.com/content/4/1/16
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pretreatment with sulindac sulfide (Figure 3). There was
no effect of drug or EGF treatment on total ERK1/2
expression.
The effect of sulindac sulfone on EGF-induced phosphor-
ylation of EGFR and ERK1/2 was also examined. As seen
with sulindac sulfide, pretreatment of HT29 cells for 24 h
with 200–800 µM sulindac sulfone markedly decreased
the ability of EGF to induce phosphorylation of EGFR;
total EGFR expression levels and ERK1/2 phosphorylation
were also downregulated (Figure 4), albeit to a lesser
extent than with sulindac sulfide.
The finding that total EGFR protein expression was
decreased by sulindac metabolites (Figures 3 and 4) was
unexpected; we therefore confirmed these results using a
second antibody (Biosource catalog #AHR5062). The
confirmatory EGFR antibody is an EGFR antibody cocktail
(composed of four monoclonal antibodies) directed
against both the extracellular and cytoplasmic domains of
EGFR. The same downregulation of total EGFR elicited by
sulindac sulfide and sulfone was found using this anti-
body (data not shown), confirming that these results are
not peculiar to a single EGFR epitope or a result of an arti-
fact of the use of a single antibody.
Dose response of sulindac sulfide inhibition of EGFR Figure 3
Dose response of sulindac sulfide inhibition of EGFR. HT29 cells were grown to 80% confluence in medium containing 
10% FBS then serum deprived for 24 h before addition of drug. Cells were then treated with vehicle (0.1% DMSO), 40, 80, 120, 
or 160 µM sulindac sulfide, drug doses previously shown to induce apoptotic cell death in these cells. Twenty four hours after 
drug treatment, vehicle or 10 ng/ml EGF was added and cells were harvested 10 min later. (A) Immunoblots were performed 
on cell lysates with antibodies raised against pEGFR (pY1068), total EGFR, pERK1/2, total ERK1/2, and caspase-3; total ERK1/2 
immunoblots served as loading controls. The graphs show the densitometry results of the pEGFR bands (B) and total EGFR 
bands (C). Results shown in figure are representative of 3 separate experiments.Journal of Carcinogenesis 2005, 4:16 http://www.carcinogenesis.com/content/4/1/16
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EGF had no effect on morphological apoptosis or activa-
tion of caspase-3 but treatment with 40–160 µM sulindac
sulfide (Figure 3) or 600–800 µM sulindac sulfone (Figure
4) induced substantial apoptotic cell death, as determined
by cleavage of caspase-3 and confirmed with the acridine
orange and ethidium bromide morphologic assay (data
not shown).
Sulindac metabolites downregulate basal EGFR 
phosphorylation and expression
Next we examined the time course of sulindac's effects on
EGFR expression and phosphorylation in cells grown in
10% FBS (basal conditions). Phosphorylation of EGFR
and total EGFR protein expression were downregulated as
early as 12 h and persisted at 24 h following sulindac
sulfide treatment (Figure 5). Significant downregulation
of pERK1/2 was not detected prior to 24 h in these exper-
iments. Evidence of apoptosis, by presence of caspase-3
cleavage products (Figure 5A) was also first detected at 24
h; examination of nuclear morphology after staining with
acridine orange and ethidium bromide at 48 h confirmed
cleaved caspase-3 immunoblot results (data not shown).
Sulindac sulfide treatment did not consistently affect lev-
els of total ERK1/2 or α-tubulin proteins. For this experi-
ment immunoblots for each time point were run on
individual gels thus, only samples within a single time
point, assayed for one particular protein, can be directly
compared.
Dose response of sulindac sulfone inhibition of EGFR Figure 4
Dose response of sulindac sulfone inhibition of EGFR. HT29 cells were grown to 80% confluence in medium containing 
10% FBS then serum deprived for 24 h before addition of drug. Cells were then treated with vehicle (0.2% DMSO), 200, 400, 
600, or 800 µM sulindac sulfone, drug doses previously shown to induce apoptotic cell death in these cells. Twenty four hours 
after drug treatment, vehicle or 10 ng/ml EGF was added and cells were harvested 10 min later. (A) Immunoblots were per-
formed on cell lysates with antibodies raised against pEGFR (pY1068), total EGFR, pERK1/2, total ERK1/2, and caspase-3; total 
ERK1/2 immunoblots served as loading controls. The graphs show the densitometry results of the pEGFR bands (B) and total 
EGFR bands (C). Results shown in figure are representative of 3 separate experiments.Journal of Carcinogenesis 2005, 4:16 http://www.carcinogenesis.com/content/4/1/16
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The effect of sulindac sulfone on basal EGFR activation
and expression was also examined. Sulindac sulfone treat-
ment resulted in a modest but significant decrease in
EGFR phosphorylation as early as 1 h after treatment, and
this effect increased and persisted through 24 h (Figure 6A
and 6B). Downregulation of total EGFR (Figure 6A and
6C) and pERK1/2 (Figure 6A) proteins was first seen at 24
h; caspase-3 cleavage (Figure 6A) was also first detected at
24 h. Morphologic evidence of apoptosis was apparent at
48 h, the earliest time point examined in this manner. Sul-
fone treatment did not consistently affect levels of total
ERK1/2 or α-tubulin proteins.
To exclude the possibility that downregulation of EGFR by
sulindac metabolites was unique to HT29 cells, similar
experiments were carried out in Caco-2 and HCT116 cells.
Dose response and time course of sulindac sulfide inhibition of EGFR Figure 5
Dose response and time course of sulindac sulfide inhibition of EGFR. HT29 cells were grown to confluence in 
medium containing 10% FBS and treated with vehicle (0.1% DMSO), 160, or 180 µM sulindac sulfide for 1 h, 12 h, and 24 h. 
Cells were then harvested and immunoblots were performed on cell lysates with antibodies raised against pEGFR (pY1068), 
total EGFR, pERK1/2, total ERK1/2, and cleaved caspase-3; α-tubulin immunoblots of the same lysates served as loading con-
trols. (A) 1 h, 12 h, and 24 h immunoblot results. The graphs show the densitometry results of the pEGFR bands (B) and total 
EGFR bands (C). Data represent mean of triplicate samples ± SD; statistical significance is denoted by **p < 0.01 and ***p < 
0.001 versus respective time point vehicle. Results shown in figure are representative of 2 separate experiments each with trip-
licate samples.Journal of Carcinogenesis 2005, 4:16 http://www.carcinogenesis.com/content/4/1/16
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Sulindac sulfide and sulfone downregulated expression of
both pEGFR and total EGFR in these cell lines as well
(data not shown).
ZVAD blocks sulindac-induced apoptosis but not EGFR 
downregulation
Although the downregulation of EGFR observed with
sulindac metabolites occurred prior to either biochemical
or morphologic evidence of apoptosis, it remains possible
that some of the decrease in EGFR protein expression
could be a consequence of caspase activation by sulindac
metabolites. To examine this possibility, HT29 cells were
pretreated with vehicle or 25 µM of the broad specificity
caspase inhibitor ZVAD-fmk (ZVAD) for 60 minutes prior
to treatment with 600 µM sulindac sulfone or vehicle for
48 h. ZVAD pretreatment completely blocked sulindac
sulfone induced apoptosis as measured by examination of
nuclear morphology (Figure 7A) and it prevented cleavage
of caspase 3 to the active 17 and 19 kDa fragments (Figure
7B; the 20 kDa caspase 3 fragment seen with the
Dose response and time course of sulindac sulfone inhibition of EGFR Figure 6
Dose response and time course of sulindac sulfone inhibition of EGFR. HT29 cells were grown to confluence in 
medium containing 10% FBS followed by treatment with vehicle (0.2% DMSO), 400, or 600 µM sulindac sulfone for 1 h, 12 h, 
and 24 h. Cells were then harvested and immunoblots were performed on cell lysates with antibodies raised against pEGFR 
(pY1068), total EGFR, pERK1/2, total ERK1/2, and cleaved caspase-3; α-tubulin immunoblots of the same lysates served as 
loading controls. (A) 1 h, 12 h, and 24 h Western blot results. The graphs show the densitometry results of the pEGFR bands 
(B) and total EGFR bands (C). Data represent mean of triplicate samples ± SD; statistical significance is denoted by **p < 0.01 
and ***p < 0.001 versus respective time point vehicle. Results shown in figure are representative of 2 separate experiments 
each with triplicate samples.Journal of Carcinogenesis 2005, 4:16 http://www.carcinogenesis.com/content/4/1/16
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combination of sulfone and ZVAD has been shown to be
an inactive cleavage product [26-29]. While 25 uM ZVAD
prevented both caspase activation and morphologic
apoptosis induced by sulindac sulfone, it did not prevent
sulindac sulfone induced decreases in either total or
pEGFR (Figure 7B–D). Combination experiments with
ZVAD and sulindac sulfide showed similar results as those
shown in Figure 7 for sulindac sulfone. These results dem-
onstrate that downregulation of EGFR by sulindac metab-
olites is not a consequence of the apoptotic effect of these
drugs.
Discussion
Our laboratory originally reported that sulindac metabo-
lites inhibit the EGFR/mitogen activated protein kinase
(MAPK)/ERK1/2 signaling pathway at the level of MEK or
higher [5] (Figure 1) and that the downregulation of
mitogen-activated protein kinase kinase (MEK)/ERK1/2 is
Effect of the caspase inhibitor, ZVAD, on apoptosis and inhibition of EGFR Figure 7
Effect of the caspase inhibitor, ZVAD, on apoptosis and inhibition of EGFR. HT29 colon cancer cells were grown to 
confluence in medium containing 10% FBS followed by pretreatment with or without 25 µM zvad for 1 h. Cells were then 
treated with vehicle (0.2% DMSO) or 600 µM sulfone for 48 h. Cells were harvested and immunoblots were performed on cell 
lysates with antibodies raised against pEGFR (pY1068), total EGFR, and cleaved caspase 3; α-tubulin immunoblots of the same 
lysates served as loading controls. The graphs show morphological apoptosis results (A) 48 h Western immunoblot results 
(B) and densitometry of the pEGFR bands (C) and total EGFR bands (D). Data represent mean of triplicate samples ± SD; sta-
tistical significance is denoted by *p < 0.05, **p < 0.01 and ***p < 0.001. Results shown in figure are representative of 2 sepa-
rate experiments each with triplicate samples.Journal of Carcinogenesis 2005, 4:16 http://www.carcinogenesis.com/content/4/1/16
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both necessary and sufficient for the apoptotic effect of
these drugs [8]. We now report, for the first time, that
sulindac metabolites inhibit EGFR phosphorylation and
downregulate the expression of total EGFR protein in
human colon cancer cells. Downregulation of EGFR
occurred at doses and within a time course that is consist-
ent with the possibility that the effect of drug on the EGFR
could be the mechanism of the inhibition of MEK1/2 and
ERK1/2 activity and apoptotic cell death induced by these
drugs.
Both sulindac sulfide and sulindac sulfone downregulate
EGFR expression and phosphorylation at comparable
doses to those that inhibit ERK1/2 phosphorylation and
induce apoptotic cell death (Figures 5 and 6). The time
course experiments suggest that the kinetics of the EGFR
effect may differ between the two sulindac metabolites.
With sulindac sulfide, the effect on EGFR and ERK1/2
occurred concurrently (first seen at 12 h) and before any
detectable effect on apoptosis. This suggests that the
downregulation of EGFR may be responsible for some or
all of the ERK1/2 inhibitory effects of the drug. The rela-
tionship between sulindac sulfone's effect on EGFR and
ERK1/2 is not as clear since an effect on pEGFR was
detected substantially earlier (1 hour) than the effect on
pERK1/2 and apoptosis (24 hours). These differences in
the kinetics of the two sulindac metabolites on pEGFR
and pERK1/2 downregulation could represent differences
in potency, duration of effect, the spectrum of EGFR phos-
phorylation sites that are affected by the different drugs,
differential effects on phosphatases, and/or differences in
the molecular mechanism of action. Similar to our results,
Jimeno et al. reported that treatment of HuCCT cells with
the EGFR tyrosine kinase inhibitor (TKI) erlotinib or the
mononclonal antibody (MAb) cetuximab led to signifi-
cant downregulation of pEGFR as early as 1 h following
treatment whereas major downstream effectors (pERK1/2
and pAKT) were not coordinately affected [18]. Despite
these differences in kinetics, the finding that EGFR down-
regulation was observed consistently with both sulindac
metabolites and in three different CRC cell lines (HT29,
HCT116, and Caco-2) establishes the EGFR as a new tar-
get of sulindac.
Activation of the EGFR pathway is particularly common in
colorectal cancers [19-22] and overexpression of EGFR
correlates with more aggressive disease and poor progno-
sis [23-26]. Both EGFR MAbs and TKIs that block activa-
tion of EGFR are now being used for the treatment of
colorectal cancer [27]. In light of our evidence that
NSAIDs downregulate EGFR signaling and induce apop-
tosis, it is interesting to note that both EGFR MAbs and
TKIs have been shown to stimulate important pro-apop-
totic genes and downregulate anti-apoptotic genes, partic-
ularly those of the Bcl-2 family [28-30]. Furthermore,
treatment with combinations of agents that inhibit EGFR
by different mechanisms is more effective than treatment
with a single agent. For example, the combination of erlo-
tinib plus cetuximab caused a synergistic induction of
apoptosis in vitro, and an additive effect on tumor growth
arrest in vivo [18]. Thus, downregulation of EGFR could
mediate the apoptotic and chemopreventive effects of
NSAIDs and could explain some of the clinical evidence of
additive growth inhibitory effects of EGFR inhibitors and
NSAIDs. These data suggest a biochemical rationale for
the use of combinations of classic EGFR inhibitors and
NSAIDs in the treatment or prevention of CRC.
If inhibition of EGFR signaling is a mechanism of NSAIDs
as our data indicates, it will be of great interest to examine
the full spectrum of possible consequences of downregu-
lation of EGFR. Thus far, we have only examined the ras-
raf-MEK1/2-ERK1/2 arm of EGFR signaling but several
other signaling pathways are known to be activated by the
EGFR including the phosphatidylinositol-3-kinase (PI3-
K) and Janus kinase (JAK)-signal transducers and
activators of transcription (STAT) pathways [31]. Sulindac
metabolites may also affect other members of the ErbB
family of receptor tyrosine kinases (RTK) including Erb2,
ErbB3, ErbB4, non-ErbB RTKs including PDGFR and
VEGFR, and/or receptors lacking tyrosine kinase activity
such as the adenosine receptor. Studies to examine the
effect of NSAIDs on these pathways and receptors are
underway.
We have not systematically examined the mechanism by
which sulindac metabolites downregulate EGFR but the
relatively short time course (as early as 1 hour) suggests
that the effect is more likely due to increased degradation
of EGFR rather than inhibition of new protein synthesis.
Our data demonstrate that EGFR inhibition is not a con-
sequence of caspase activation or due to the apoptotic
effects of the drugs in that apoptosis was first detected 24
h after sulindac metabolite treatment, whereas
downregulation of EGFR was seen as early as 1 to 12 hours
after drug treatment. In addition, inhibition of apoptosis
with the broad specificity caspase inhibitor ZVAD did not
prevent EGFR downregulation by sulindac metabolites.
Thus, we hypothesize that EGFR downregulation by sulin-
dac metabolites is not due to activation of caspases, but
rather is a result of increased proteasomal and/or lyso-
somal degradation. Further studies are warranted to deter-
mine the precise mechanism of EGFR downregulation by
sulindac metabolites.
Sulindac metabolites decreased expression of both total
and pEGFR proteins. The time course experiments, partic-
ularly those with sulindac sulfone (Figure 6), suggest that
downregulation of these two forms of the receptor could
be occurring by distinct mechanisms. Although total andJournal of Carcinogenesis 2005, 4:16 http://www.carcinogenesis.com/content/4/1/16
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pEGFR downregulation with sulindac sulfide occurred
concurrently, the sulfone metabolite decreased pEGFR as
early as 1 h whereas downregulation of total EGFR protein
was first observed at the 24 h time point. This sequence
indicates that the downregulation of pEGFR is not likely
to be a consequence of the downregulation of the total
receptor, at least with sulindac sulfone.
Conclusion
In summary, we have described for the first time that
sulindac metabolites downregulate EGFR and prevent
EGFR phosphorylation by EGF. This effect may explain, at
least in part, our previous observation that these drugs
inhibit basal and EGF-induced activation of the MEK/ERK
arm of the EGFR signaling pathway. Downregulation of
EGFR was shown to be independent of COX inhibitory
activity as it occurred with sulindac sulfone. These results
add to the increasing amount of data that suggest interac-
tions exist between the effects of NSAIDs and EGFR sign-
aling [13,14]. Our results are the first to suggest that these
interactions are due to a direct drug effect on the EGFR
itself.
Abbreviations
NSAID, non-steroidal anti-inflammatory drug; CRC,
colorectal cancer; ERK1/2, extracellular-signal regulated
kinase; EGF, epidermal growth factor; EGFR, epidermal
growth factor receptor; pEGFR, phosphorylated epidermal
growth factor receptor; pERK1/2, phosphorylated extra-
cellular-signal regulated kinase 1/2; COX, cyclooxygenase;
FAP, familial adenomatous polyposis; FBS, fetal bovine
serum; PBS, phosphate buffered saline; MAPK, mitogen-
activated protein kinase; MEK1/2, mitogen-activated pro-
tein kinase kinase; MAb, monoclonal antibody; TKI, tyro-
sine kinase inhibitor; PI3-K, phosphatidylinositol-3-
kinase; JAK/STAT, Janus kinase/signal transducers and
activators of transcription; RTK, receptor tyrosine kinase
Acknowledgements
Funding provided by Department of Veterans Affairs Merit Review Pro-
gram and Cancer Research and Prevention Foundation
References
1. Jemal A, Murray T, Ward E, Samuels A, Tiwari RC, Ghafoor A, Feuer
EJ, Thun MJ: Cancer statistics, 2005.  CA Cancer J Clin 2005,
55(1):10-30.
2. Gupta RA, Dubois RN: Colorectal cancer prevention and treat-
ment by inhibition of cyclooxygenase-2.  Nat Rev Cancer 2001,
1(1):11-21.
3. Thun MJ, Henley SJ, Patrono C: Nonsteroidal anti-inflammatory
drugs as anticancer agents: mechanistic, pharmacologic, and
clinical issues.  J Natl Cancer Inst 2002, 94(4):252-66.
4. Rice PL, Kelloff J, Sullivan H, Driggers LJ, Beard KS, Kuwada S, Piazza
G, Ahnen DJ: Sulindac metabolites induce caspase- and pro-
teasome-dependent degradation of beta-catenin protein in
human colon cancer cells.  Mol Cancer Ther 2003, 2(9):885-92.
5. Rice PL, Goldberg RJ, Ray EC, Driggers LJ, Ahnen DJ: Inhibition of
extracellular signal-regulated kinase 1/2 phosphorylation
and induction of apoptosis by sulindac metabolites.  Cancer Res
2001, 61(4):1541-7.
6. Rice PL, Washington M, Schleman S, Beard KS, Driggers LJ, Ahnen DJ:
Sulindac sulfide inhibits epidermal growth factor-induced
phosphorylation of extracellular-regulated kinase 1/2 and
Bad in human colon cancer cells.  Cancer Res 2003, 63(3):616-20.
7. Piazza GA, Alberts DS, Hixson LJ, Paranka NS, Li H, Finn T, Bogert C,
Guillen JM, Brendel K, Gross PH, Sperl G, Ritchie J, Burt RW,
Ellsworth L, Ahnen DJ, Pamukcu R: Sulindac sulfone inhibits
azoxymethane-induced colon carcinogenesis in rats without
reducing prostaglandin levels.  Cancer Res 1997, 57(14):2909-15.
8. Rice PL, Beard KS, Driggers LJ, Ahnen DJ: Inhibition of extracellu-
lar-signal regulated kinases 1/2 is required for apoptosis of
human colon cancer cells in vitro by sulindac metabolites.
Cancer Res 2004, 64(22):8148-51.
9. Coffey RJ, Hawkey CJ, Damstrup L, Graves-Deal R, Daniel VC,
Dempsey PJ, Chinery R, Kirkland SC, DuBois RN, Jetton TL, Morrow
JD:  Epidermal growth factor receptor activation induces
nuclear targeting of cyclooxygenase-2, basolateral release of
prostaglandins, and mitogenesis in polarizing colon cancer
cells.  Proc Natl Acad Sci U S A 1997, 94(2):657-62.
10. DuBois RN, Awad J, Morrow J, Roberts LJ 2nd, Bishop PR: Regula-
tion of eicosanoid production and mitogenesis in rat intesti-
nal epithelial cells by transforming growth factor-alpha and
phorbol ester.  J Clin Invest 1994, 93(2):493-8.
11. Kokoska ER, Smith GS, Miller TA: Nonsteroidal anti-inflamma-
tory drugs attenuate proliferation of colonic carcinoma cells
by blocking epidermal growth factor-induced Ca++
mobilization.  J Gastrointest Surg 2000, 4(2):150-61.
12. Torrance CJ, Jackson PE, Montgomery E, Kinzler KW, Vogelstein B,
Wissner A, Nunes M, Frost P, Discafani CM: Combinatorial che-
moprevention of intestinal neoplasia.  Nature Med 2000,
6:1024-1028.
13. Kokoska ER, Smith GS, Wolff AB, Deshpande Y, Miller TA: Nonster-
oidal anti-inflammatory drugs attenuate epidermal growth
factor-induced proliferation independent of prostaglandin
synthesis inhibition.  J Surg Res 1999, 84(2):186-92.
14. Kinoshita T, Takahashi Y, Sakashita T, Inoue H, Tanabe T, Yoshimoto
T: Growth stimulation and induction of epidermal growth
factor receptor by overexpression of cyclooxygenases 1 and
2 in human colon carcinoma cells.  Biochim Biophys Acta 1999,
1438(1):120-30.
15. Winde G, Lugering N, Glodny B, Schmid KW, Muller O, Senninger N,
Osswald H: Decreased HER-2 tyrosine kinase expression in
rectal mucosa of FAP patients following low-dose sulindac
chemoprevention.  Cancer Lett 1998, 134(2):201-7.
16. Duke R, Cohen JJ: Morphological and biochemical assays of
apoptosis.  In Current Protocols in Immunology Edited by: K Coligan JE,
AM, Margulies DJ, Shevach EM, Strober W. Wiley-Interscience: New
York; 1992:3.17.1-3.17.16. 
17. Lowry OHRN, Farr AL, Randall RJ: Protein measurement with
the folin phenol reagent.  J Biol Chem 1951, 193:265-275.
18. Jimeno A, Rubio-Viqueira B, Amador ML, Oppenheimer D, Bouraoud
N, Kulesza P, Sebastiani V, Maitra A, Hidalgo M: Epidermal growth
factor receptor dynamics influences response to epidermal
growth factor receptor targeted agents.  Cancer Res 2005,
65(8):3003-10.
19. Messa C, Russo F, Caruso MG, Di Leo A: EGF, TGF-alpha, and
EGF-R in human colorectal adenocarcinoma.  Acta Oncol 1998,
37(3):285-9.
20. Salomon DS, Brandt R, Ciardiello F, Normanno N: Epidermal
growth factor-related peptides and their receptors in human
malignancies.  Crit Rev Oncol Hematol 1995, 19(3):183-232.
21. Kirschbaum MH, Yarden Y: The ErbB/HER family of receptor
tyrosine kinases: A potential target for chemoprevention of
epithelial neoplasms.  J Cell Biochem Suppl 2000, 34:52-60.
22. O'Dwyer PJ, Benson AB 3rd: Epidermal growth factor receptor-
targeted therapy in colorectal cancer.  Semin Oncol 2002, 29(5
Suppl 14):10-7.
23. Yasui W, Sumiyoshi H, Hata J, Kameda T, Ochiai A, Ito H, Tahara E:
Expression of epidermal growth factor receptor in human
gastric and colonic carcinomas.  Cancer Res 1988, 48(1):137-41.
24. Skibber J, Minsky BD, Hoff P: Cancer of the colon, in Cancer:
Principles and Practice of Oncology.  Edited by: HS DeVita VT,
Rosenberg SA. Lippincott Williams & Wilkins: Philadelphia;
2001:1216-1270. 
25. Mayer A, Takimoto M, Fritz E, Schellander G, Kofler K, Ludwig H:
The prognostic significance of proliferating cell nuclear anti-Publish with BioMed Central    and   every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published  immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
Journal of Carcinogenesis 2005, 4:16 http://www.carcinogenesis.com/content/4/1/16
Page 12 of 12
(page number not for citation purposes)
gen, epidermal growth factor receptor, and mdr gene
expression in colorectal cancer.  Cancer 1993, 71(8):2454-60.
26. Radinsky R: Modulation of tumor cell gene expression and
phenotype by the organ-specific metastatic environment.
Cancer Metastasis Rev 1995, 14(4):323-38.
27. Jimeno A, Hidalgo M: Blockade of epidermal growth factor
receptor (EGFR) activity.  Crit Rev Oncol Hematol 2005,
53(3):179-92.
28. Jost M, Class R, Kari C, Jensen PJ, Rodeck U: A central role of Bcl-
X(L) in the regulation of keratinocyte survival by autocrine
EGFR ligands.  J Invest Dermatol 1999, 112(4):443-9.
29. Kari C, Chan TO, Rocha de Quadros M, Rodeck U: Targeting the
epidermal growth factor receptor in cancer: apoptosis takes
center stage.  Cancer Res 2003, 63(1):1-5.
30. Wu X, Rubin M, Fan Z, DeBlasio T, Soos T, Koff A, Mendelsohn J:
Involvement of p27KIP1 in G1 arrest mediated by an anti-
epidermal growth factor receptor monoclonal antibody.
Oncogene 1996, 12(7):1397-403.
31. Jorissen RN, Walker F, Pouliot N, Garrett TP, Ward CW, Burgess
AW: Epidermal growth factor receptor: mechanisms of acti-
vation and signalling.  Exp Cell Res 2003, 284(1):31-53.